Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Brognard

Showing results (31-40 of 55) with videos related to

Pageof 6
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|July 10, 2013
Targeted genetic dependency screen facilitates identification of actionable mutations in FGFR4, MAP3K9, and PAK5 in lung cancerShameem Fawdar, Eleanor W Trotter, Yaoyong Li, et al.
Journal of Medicinal Chemistry|August 29, 2024
Selective Degradation of MLK3 by a Novel CEP1347-VHL-02 PROTAC Compound Limits the Oncogenic Potential of TNBCKamila Karpińska, Dawid Mehlich, Venkata R Sabbasani, et al.
Science Signaling|April 19, 2018
Truncation- and motif-based pan-cancer analysis reveals tumor-suppressing kinasesAndrew M Hudson, Natalie L Stephenson, Cynthia Li, et al.
Oncogene|December 16, 2018
Upregulation of MLK4 promotes migratory and invasive potential of breast cancer cellsAnna A Marusiak, Monika K Prelowska, Dawid Mehlich, et al.
Cancer Research|April 17, 2004
Preferential inhibition of Akt and killing of Akt-dependent cancer cells by rationally designed phosphatidylinositol ether lipid analoguesS Sianna Castillo, John Brognard, Pavel A Petukhov, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 10, 2025
CRISPR screens and quantitative proteomics reveal remodeling of the aryl hydrocarbon receptor-driven proteome through PARP7 activityAndrii Gorelik, Joao A Paulo, Christina B Schroeter, et al.
The Journal of Biological Chemistry|August 1, 2024
The SRC family kinase inhibitor NXP900 demonstrates potent antitumor activity in squamous cell carcinomasSweta Dash, Sabrina Hanson, Ben King, et al.
Research Square|May 25, 2026
A first-in-class precision antibody conjugate targeting EGFR, mTOR, and PI3K to treat head and neck cancersMartin Schnermann, Xiaoyi Li, Meghri Katerji, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 10, 2014
Pleckstrin homology domain leucine-rich repeat protein phosphatases set the amplitude of receptor tyrosine kinase outputGloria Reyes, Matt Niederst, Ksenya Cohen-Katsenelson, et al.
Cell|January 27, 2015
Cancer-associated protein kinase C mutations reveal kinase's role as tumor suppressorCorina E Antal, Andrew M Hudson, Emily Kang, et al.
Pageof 6

Showing results (31-40 of 55) with videos related to

Sort By:
Pageof 6
Proceedings of the National Academy of Sciences of the United States of America|July 10, 2013
Targeted genetic dependency screen facilitates identification of actionable mutations in FGFR4, MAP3K9, and PAK5 in lung cancerShameem Fawdar, Eleanor W Trotter, Yaoyong Li, et al.
Journal of Medicinal Chemistry|August 29, 2024
Selective Degradation of MLK3 by a Novel CEP1347-VHL-02 PROTAC Compound Limits the Oncogenic Potential of TNBCKamila Karpińska, Dawid Mehlich, Venkata R Sabbasani, et al.
Science Signaling|April 19, 2018
Truncation- and motif-based pan-cancer analysis reveals tumor-suppressing kinasesAndrew M Hudson, Natalie L Stephenson, Cynthia Li, et al.
Oncogene|December 16, 2018
Upregulation of MLK4 promotes migratory and invasive potential of breast cancer cellsAnna A Marusiak, Monika K Prelowska, Dawid Mehlich, et al.
Cancer Research|April 17, 2004
Preferential inhibition of Akt and killing of Akt-dependent cancer cells by rationally designed phosphatidylinositol ether lipid analoguesS Sianna Castillo, John Brognard, Pavel A Petukhov, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 10, 2025
CRISPR screens and quantitative proteomics reveal remodeling of the aryl hydrocarbon receptor-driven proteome through PARP7 activityAndrii Gorelik, Joao A Paulo, Christina B Schroeter, et al.
The Journal of Biological Chemistry|August 1, 2024
The SRC family kinase inhibitor NXP900 demonstrates potent antitumor activity in squamous cell carcinomasSweta Dash, Sabrina Hanson, Ben King, et al.
Research Square|May 25, 2026
A first-in-class precision antibody conjugate targeting EGFR, mTOR, and PI3K to treat head and neck cancersMartin Schnermann, Xiaoyi Li, Meghri Katerji, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 10, 2014
Pleckstrin homology domain leucine-rich repeat protein phosphatases set the amplitude of receptor tyrosine kinase outputGloria Reyes, Matt Niederst, Ksenya Cohen-Katsenelson, et al.
Cell|January 27, 2015
Cancer-associated protein kinase C mutations reveal kinase's role as tumor suppressorCorina E Antal, Andrew M Hudson, Emily Kang, et al.
Pageof 6